Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and a...
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 201...
Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly d...
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with adv...
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan foll...
